Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06865105 · ClinicalTrials.gov registry record · Phase 2

Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis

A Phase 2 study of Psoriatic Arthritis, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06865105 is a Phase 2 study of Psoriatic Arthritis that is actively recruiting participants, run by AbbVie. The registered enrollment target is 120 participants, below the 850-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06865105, a Phase 2 study of Psoriatic Arthritis, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies through a series of substudies, for the treatment of active psoriatic arthritis and to assess the changes in disease symptoms. The therapies being assessed in this sub-study are risankizumab and lutikizumab. Participants will be randomized in a 1:1:1 ratio to one of the three treatment arms: lutikizumab monotherapy, risankizumab monotherapy or a combination therapy of lutikizumab and risankizumab. Around 120 participants will be enrolled in the study at approximately 40 sites worldwide. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions Studied

Psoriatic Arthritis

Interventions

  • DRUG Lutikizumab
  • DRUG Risankizumab

Study Locations (20)

Florida

  • Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085 - Avon Park
  • Clinical Research Of West Florida - Phase I Unit /ID# 273198 - Clearwater
  • HMD Research LLC /ID# 273086 - Orlando
  • West Broward Rheumatology Associates /ID# 272892 - Tamarac
  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199 - Tampa

Texas

  • Tekton Research - West Gate /ID# 272765 - Austin
  • Accurate Clinical Research - Houston /ID# 272754 - Houston
  • Tekton Research, LLC /ID# 272901 - San Antonio
  • Dynamed Clinical Research - Tomball /ID# 272760 - Tomball

Illinois

  • Clinic Of Dr. Robert Hozman/Clinical Investigation Specialists, Inc /ID# 272879 - Skokie
  • Willow Rheumatology and Wellness, PLLC /ID# 277354 - Willowbrook

California

  • Newport Huntington Medical Group /ID# 272764 - Huntington Beach

Maryland

  • Klein And Associates /ID# 272829 - Hagerstown

Ohio

  • Paramount Medical Research and Consulting /ID# 272757 - Middleburg Heights

Pennsylvania

  • Altoona Center For Clinical Research /ID# 272593 - Duncansville

Tennessee

  • Private Practice - Dr. Ramesh C. Gupta I /ID# 272897 - Memphis

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-04-11
Est. Completion 2028-01
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06865105

The ClinicalTrials.gov registry entry for NCT06865105 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 850-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (86% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Lutikizumab is the first listed.

NCT06865105 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Texas, Illinois.

Frequently Asked Questions

What is clinical trial NCT06865105 about?

NCT06865105 is a clinical study titled "Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis". Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. This study will evaluate the efficacy and safety of targeted therapies th...

What is the current status of trial NCT06865105?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-04-11. Estimated completion is 2028-01.

What conditions does trial NCT06865105 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT06865105?

The interventions under investigation include: Lutikizumab (DRUG), Risankizumab (DRUG).

Who is sponsoring clinical trial NCT06865105?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06865105 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Psoriatic Arthritis

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.